staging.omvohinuae.com Open in urlscan Pro
162.214.96.162  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Prescribing Information
 * Home
 * Patient
 * Product Overview
 * Efficacy
 * Safety
 * Dosing
 * Latest Updates
 * Videos


OMVOH NOW APPROVED

The first and only approved
IL-23p19 inhibitor for moderate to
severe ulcerative colitis patients


READY FOR AN URGENT CHANGE?

Omvoh the first & only approved IL-23p19 inhibitor for moderate to severe
ulcerative colitis patients


GETTING STARTED WITH OMVOH

Omvoh the first & only approved IL-23p19 inhibitor for moderate to severe
ulcerative colitis patients

Previous Next


ABOUT ULCERATIVE COLITIS

 * What is ulcerative colitis?
 * What is bowel urgency?

Ulcerative colitis (UC) is a chronic inflammatory disease that affects the colon
in the gastrointestinal (GI) tract. UC-related inflammation can damage the
lining in the colon. This inflammation can lead to symptoms such as bowel
urgency, blood in stool, and frequent bowel movements that can get worse over
time if left untreated.

BOWEL URGENCY IS A COMMON SYMPTOM OF ULCERATIVE COLITIS.*

OVER 80% OF PEOPLE WITH ULCERATIVE COLITIS REPORTED EXPERIENCING BOWEL URGENCY.*

*Studies conducted in multiple countries.

BOWEL URGENCY FROM ULCERATIVE COLITIS IS THE SUDDEN AND IMMEDIATE NEED TO USE
THE BATHROOM.

IF YOU HAVE ULCERATIVE COLITIS AND YOU ONLY HAVE MOMENTS TO MAKE IT TO THE
BATHROOM—THAT’S BOWEL URGENCY.

*Study conducted in Poland.


MAKE THE URGENT CHANGE WITH OMVOH

Omvoh helped patients achieve sustained clinical remission and reduced bowel
urgency severity

SUSTAINED CLINICAL REMISSION



50% of patients achieved clinical remission at week 52 with Omvoh

REDUCES THE DISRUPTIVE IMPACT OF BOWEL URGENCY



43% of patients taking Omvoh achieved bowel urgency remission at week 52

WELL TOLERATED SAFETY PROFILE FROM TWO PHASE 3 TRIALS



<span class=”green_txt”>Well tolerated</span> with similar adverse events and
discontinuation rates comparable to placebo through 52 weeks


CONSIDERING A DIFFERENT TREATMENT FOR YOUR UC PATIENTS?

Dr. Peter Irving discusses how patients achieved clinical remission with Omvoh
in the LUCENT trial

WATCH NOW


If you look at the efficacy data from the LUCENT trials, Omvoh demonstrated
superiority compared to placebo on all primary and key secondary endpoints.

– Dr. Peter Irving



REFERENCES

 1. Omvoh Summary of Product Characteristics, Eli Lilly, UAE, 2024.
 2. PLACEHOLDER. Mirikizumab demonstrates superiority over placebo in phase 3
    maintenance study in ulcerative colitis, supporting regulatory submissions
    in 2022. Eli Lilly and Company. December 14, 2021. Accessed May 18, 2022.
    https://investor.lilly.com/news-releases/news-release-details/mirikizumabdemonstrates-superiority-over-placebo-phase-3
 3. Carpio D, López-Sanromán A, Calvet X, et al. Perception of disease burden
    and treatment satisfaction in patients with ulcerative colitis from
    outpatient clinics in Spain: UC-LIFE survey. Eur J Gastroenterol Hepatol.
    2016;28(9):1056-1064. doi:10.1097/MEG.0000000000000658
 4. PLACEHOLDER (For primary LUCENT-2 manuscript)

 * PP-MRAE-0079
 * Privacy Policy
 * Prescribing information



For adverse events and safety reporting, please send an email: PV-MEA@lilly.com,
For product complaints, please send an email: lbmail_pc_mena@lilly.com For
further information about Lilly and Lilly products please contact us at the
below address: UAE: Bldg. 25 - 6th Floor, Dubai Health CareCity, Dubai, UAE,
P.O. Box #25319, Tel.: (+971 4)453 7800, Fax: (+971 4) 436 2399

This content is approved by Eli Lilly and company (“Lilly”). This content is
intellectual property of Lilly and its reproduction needs Lilly's prior
permission